非2型重度哮喘的进展:从分子机制到新型治疗策略
该综述聚焦非2型(non-T2)重度哮喘,覆盖其分子机制、临床表型、病因及有前景的治疗。文章讨论非T2哮喘的信号通路,包括炎症小体激活、干扰素反应和白细胞介素-17通路,及其对亚型、进展和严重程度的贡献。理解非T2哮喘的分子机制和遗传决定因素可为重度哮喘精准治疗奠定基础。
要点
- 非T2哮喘常见于重度和/或激素抵抗性哮喘患者。
- 非T2哮喘涉及炎症小体激活、干扰素反应和IL-17通路。
- 理解非T2哮喘分子机制有助于实现精准医学治疗。
核心结论
- 非T2重度哮喘的分子机制、临床表型和新型治疗策略是当前研究重点。
- 炎症小体激活、干扰素反应和IL-17通路参与非T2哮喘的亚型、进展和严重程度。
- 理解非T2哮喘的分子机制和遗传决定因素可为基础精准医学治疗重度哮喘提供依据。
研究设计与样本
- 综述类文章,检索范围未在摘要中明确报告。
主要发现
- 非T2哮喘常见于重度和/或激素抵抗性哮喘患者。
- 非T2哮喘涉及炎症小体激活、干扰素反应和IL-17通路等信号通路。
- 这些通路对非T2哮喘的亚型、进展和严重程度有贡献。
临床怎么用
- 临床应关注重度哮喘患者的非T2表型识别。
- 理解非T2哮喘分子机制有助于制定精准治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asthma is a prevalent pulmonary disease that affects more than 300 million people worldwide and imposes a substantial economic burden. While medication can effectively control symptoms in some patients, severe asthma attacks, driven by airway inflammation induced by environmental and infectious exposures, continue to be a major cause of asthma-related mortality. Heterogeneous phenotypes of asthma include type 2 (T2) and non-T2 asthma. Non-T2 asthma is often observed in patients with severe and/or steroid-resistant asthma. This review covers the molecular mechanisms, clinical phenotypes, causes and promising treatments of non-T2 severe asthma. Specifically, we discuss the signalling pathways for non-T2 asthma including the activation of inflammasomes, interferon responses and interleukin-17 pathways, and their contributions to the subtypes, progression and severity of non-T2 asthma. Understanding the molecular mechanisms and genetic determinants underlying non-T2 asthma could form the basis for precision medicine in severe asthma treatment.
引用
- Liu T, Woodruff PG, Zhou X, et al. Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. Eur Respir J. 2024. PMID: 38697650. doi:10.1183/13993003.00826-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。